Dengue shock syndrome
disease diseaseOn this page
Summary
Dengue shock syndrome (MONDO:0000248) is a disease and 7 clinical trials. Top therapeutic interventions include lactic acid, sodium chloride, and d-lactic acid. A subtype of Dengue hemorrhagic fever — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 7
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | dengue shock syndrome |
| Mondo ID | MONDO:0000248 |
| MeSH | D019595 |
| DOID | DOID:0050125 |
| SNOMED CT | 409671005 |
| UMLS | C0376300 |
| MedGen | 83958 |
| GARD | 0022736 |
| Is cancer (heuristic) | no |
Disease family
This is a subtype of Dengue hemorrhagic fever. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › primary viral infectious disease › Flaviviridae infectious disease › dengue disease › Dengue hemorrhagic fever › dengue shock syndrome
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 7.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 3 |
| PHASE3 | 1 |
| PHASE2/PHASE3 | 1 |
| PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00966628 | PHASE3 | UNKNOWN | Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients (DSS) |
| NCT04673422 | PHASE2/PHASE3 | COMPLETED | Effect of Montelukast in Preventing Dengue With Warning Signs in Dengue Patients |
| NCT00468858 | PHASE2 | COMPLETED | A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children |
| NCT00919178 | PHASE1 | COMPLETED | Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus |
| NCT06642493 | Not specified | ACTIVE_NOT_RECRUITING | Efficacy of Fresh Frozen Plasma (FFP) in Treating Thrombocytopenia in Dengue Patients |
| NCT04048837 | Not specified | COMPLETED | Prospective Study for the Evaluation of Dengue Prognostic Biomarkers in Singapore |
| NCT04837430 | Not specified | UNKNOWN | NT-proBNP and Troponin I in Dengue Children |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| LACTIC ACID | 4 | 1 |
| SODIUM CHLORIDE | 4 | 1 |
| D-LACTIC ACID | 3 | 1 |
Related Atlas pages
- Drugs: Lactic Acid, Sodium Chloride, D-Lactic Acid